Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to generate further insight into the role and effectiveness of the amide local anesthetic lidocaine as an adjuvant postoperative analgesic after adult spine surgery. The effect of perioperative intravenous lidocaine infusion on postoperative rehabilitation and the inflammatory response will also be examined.
| Condition | Intervention |
|---|---|
|
Back Pain |
Drug: Lidocaine Hydrochoride Injection, without epinephrine Drug: Normal Saline |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
| Official Title: | Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery: A Randomized Controlled Trial |
- Postanesthesia care unit(PACU)admission duration (in minutes) [ Time Frame: Assessed after discharge from PACU ] [ Designated as safety issue: No ]
- Post extubation requirement for intravenous fentanyl in operating room (Y/N and mcg/kg) [ Time Frame: Post extubation ] [ Designated as safety issue: No ]
- Time to first nurse administered morphine dose after PACU admission (in minutes) [ Time Frame: Assessed after PACU admission ] [ Designated as safety issue: No ]
- Total dose of fentanyl administered intraoperatively (mcg/kg) and in the PACU (mcg/kg) [ Time Frame: Measured post op ] [ Designated as safety issue: No ]
- Total amount of mophine administered/PCA pump demands and doses and ratio of PCA demands/doses [ Time Frame: 48-72 hours postoperative period ] [ Designated as safety issue: No ]
- Self reported VAS pain scores (on a 0-100 scale) [ Time Frame: Obtained on admissions to and upon discharge from PCAU, every 4 hours thereafter for the first 48 to 72 hours postoperatively, and at time of initial postoperative mobilization ] [ Designated as safety issue: No ]
- Side effect analysis [ Time Frame: Measurements of side effect analysis will be done postoperatively ] [ Designated as safety issue: No ]
- Pain Intensity Questionnaires [ Time Frame: BPI-SF completed at time of initial and subsequent postop visits, Roland Morris Back Pain Questionnaire completed postop and 12-14 days, 3 mos, 6 mos, 12 mos, and 24 mos postop as compared to baseline value ] [ Designated as safety issue: No ]
- Length of hospital stay [ Time Frame: From admission to discharge ] [ Designated as safety issue: No ]
- Post rehab analysis [ Time Frame: Time to first liquid oral intake, time to initial mobilization, time to discontinuation of study solution infusion, time to discharge order, and to time to actual discharge home ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2012 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
-
Drug: Lidocaine Hydrochoride Injection, without epinephrine
Inadequate pain control after spine surgery in adults can result in increased patient morbidity and length of hospital stay, whereas improved postoperative pain control has been demonstrated to have numerous physiologic benefits and to reduce postoperative complications. When administered systemically, the amide local anesthetic lidocaine has potent anti-inflammatory properties, including inhibition of the arachidonic acid cascade and production of eicosanoids and prostaglandins. Previous studies have confirmed that the continuous intravenous administration of lidocaine during and after abdominal surgery in adults improves patient rehabilitation (specifically, pain intensity, duration of ileus, incidence of nausea and vomiting), and shortens hospital stay. The beneficial anti-inflammatory properties versus untoward side effects of the local anesthetics appear superior to steroids and the non-steroidal anti-inflammatory drugs (NSAIDs). Moreover, concern and controversy exists regarding the adverse effects of NSAIDs on bone healing, particularly in adults undergoing spine surgery.
No study to date has investigated the efficacy of a continuous perioperative lidocaine infusion in the adult spine surgery population. Therefore, in this prospective, randomized, controlled trial, we will evaluate the analgesic efficacy, anti-inflammatory properties, and rehabilitation pattern with a continuous, perioperative intravenous infusion of lidocaine versus a normal saline placebo in adult patients undergoing a decompressive lumbar laminectomy for spinal canal stenosis. Subjects enrolled in this study will receive a standardized general anesthetic that is consistent with our present clinical practice. The study participants will be randomized to receive both a perioperative bolus (2 mg/kg) and subsequent intravenous infusion (3 mg/kg/hr) of the amide local anesthetic lidocaine or a normal saline placebo at an equal volume per hour. The study infusion will be continued for 90 minutes after surgery. All patients will receive ample and adequate intravenous doses of an opioid (morphine sulfate) to reduce their pain intensity to acceptable levels. Pain intensity, opioid requirements, opioid-related side effects, and both the immediate and sustained rehabilitation pattern will be assessed. In addition to plasma lidocaine levels in the active drug group, plasma C-reactive protein, cortisol, and cytokine levels (e.g., IL-6, IL-10 and TNF-α) will be obtained at a series of perioperative time points in all study patients. Postoperative cytokine levels will also be measured in the surgical drainage fluid.
Eligibility| Ages Eligible for Study: | 19 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 19 years to 80 years of age
- American Society of Anesthesiologists 1-3 status
- Undergoing lumbar laminectomy between levels L1 and S1 for decompression of degenerative lumbar canal stenosis but without fusion or internal fixation performed
Exclusion Criteria:
- American Society of Anesthesiologists 4 status
- Previous spinal fusion surgery but patient may have undergone previous lumbar laminectomy or lumbar open discectomy
- Morbid obesity (BMI > 40)
- Diagnosis of spinal metastatic cancer
- Presence of a severe or systemic bacterial infection
- Allergy to an amide local anesthetic or morphine sulfate
- History of a seizure disorder
- History of atrial or ventricular arrhythmia
- History of autonomic dysfunction (e.g., dysautonomia of diabetes)
- History of renal dysfunction, liver dysfunction or congestive heart failure
- History of substance abuse disorder
- History of major psychiatric disorder (e.g., depression, bipolar disorder, Axis II personality disorder, schizophrenia)
- Chronic opioid use of greater than 100 mg/day of morphine equivalents within 30 days prior to surgery
- Current use of a corticosteroid
- Use of a non-steroidal anti-inflammatory drug (NSAID), including low dose aspirin within the past 5 days
- Use of an arrhythmic drug within the past 7 days
- Current administration of a known potent CYP1A2 inhibitor, including zileuton (Zyflo), ciprofloxacin, enoxacin or any other fluoroquinolone antibiotic, amiodarone, mexiletine, propafenone, verapamil, cimetidine (Tagamet), famotidine (Pepcid), oral contraceptives, acyclovir (Zovirax) and ticlopidine (Ticlid) (Horn & Hansten, 2008).
- Current administration of a known potent CYP3A4 inhibitor, including erythromycin, clarithromycin, azole antifungal (ketoconazole, fluconazole), verapamil, diltiazem, and grapefruit juice (Scuderi et al., 2006).
- Pregnant females
Contacts and Locations| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35294 | |
| Principal Investigator: | Thomas R Vetter, M.D., M.P.H | University of Alabama at Birmingham |
More Information
No publications provided
| Responsible Party: | Thomas R. Vetter, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT01043211 History of Changes |
| Other Study ID Numbers: | F091105002 |
| Study First Received: | December 28, 2009 |
| Last Updated: | August 16, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Alabama at Birmingham:
|
Back Pain Lidocaine |
Additional relevant MeSH terms:
|
Back Pain Pain, Postoperative Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Postoperative Complications Pathologic Processes Epinephrine Epinephryl borate Lidocaine Analgesics Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses Mydriatics Adrenergic alpha-Agonists Sympathomimetics Vasoconstrictor Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 23, 2013